Status:
COMPLETED
Study on the Protective Effect of RIPC in Patients Undergoing Cardiac Surgery.
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Cardiac Surgery
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
To observe the effect of RIPC on the function of vital organs after cardiac surgery, and to explore its possible mechanism.
Eligibility Criteria
Inclusion
- patients with aortic valve, mitral valve, tricuspid valve, ascending aortic disease and coronary atherosclerosis who were admitted to hospital for elective valve repair, replacement, artificial vascular replacement or coronary artery bypass grafting.
- age 18-80 years old.
- No restriction on gender.
- ASA grade II\~III.
- NYHAII\~III level.
- the patient or his family member has signed the informed consent form for the clinical trial
Exclusion
- those who are disabled in the selected test.
- less than 5 years of education.
- The preoperative left ventricular ejection fraction ((LVEF)) was less than 40%.
- Myocardial infarction occurred in nearly one month.
- malignant tumor, hematological disease, severe liver and kidney dysfunction, recent severe infection, etc.
- History of nervous system, immune system and mental illness.
- recent operation history of heart, brain, lung, liver, kidney and other important organs
Key Trial Info
Start Date :
September 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 31 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04433468
Start Date
September 1 2020
End Date
March 31 2021
Last Update
July 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
180 Fenglin Road
Shanghai, China, 200032